Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 8Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Thyroid Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma 2Burkitt Lymphoma 2

Interventions

Cisplatin 13Magnetic Resonance Spectroscopy 9Specimen Handling 8Radiotherapy 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Radiotherapy, Intensity-Modulated 4Radiation 4Biopsy 4Surveys and Questionnaires 3Nivolumab 3Carboplatin 3pembrolizumab 2durvalumab 2Observation 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Docetaxel 2Disulfides 2Chemoradiotherapy 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2niraparib 1merphos 1ipatasertib 1dostarlimab 1cemiplimab 1cabozantinib 1balstilimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × Disulfides × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡